Department of Radiology, St. Elisabeth Ziekenhuis, Tilburg, the Netherlands.
AJNR Am J Neuroradiol. 2012 Mar;33(3):519-21. doi: 10.3174/ajnr.A2817. Epub 2011 Nov 24.
We analyzed the natural course of conservatively treated osteoporotic vertebral compression fractures from VERTOS II, a randomized trial of vertebroplasty and conservative therapy in 202 patients with vertebral compression fractures. We assessed the proportion of patients who developed chronic back pain and possible risk factors.
In VERTOS II, the VAS score was assessed at regular intervals until 1 year follow-up. We followed 95 conservatively treated patients until sufficient pain relief, defined as a VAS score ≤3. These patients were censured at the involved follow-up interval. In addition, baseline clinical and imaging data, and class of pain medication used in patients with a VAS score ≤3 at any follow-up interval were compared with those in patients with a VAS score >3 at every follow-up by using logistic regression analysis.
During 1 year of follow-up, 57 of 95 patients (60%) had sufficient pain relief with VAS scores ≤3. Thirty-eight patients (40%) still had pain with VAS-scores ≥4 at the last follow-up interval of 12 months, despite the use of higher class pain medication. Statistical analysis showed no risk factors.
In the VERTOS II trial, most conservatively treated patients with acute osteoporotic compression fractures had sufficient pain relief during the first 3 months. However, after 1 year, a substantial proportion of patients still had disabling pain despite higher class pain medication used. There were no predictors for the development of chronic pain. Patients with continuing pain ≥3 months after the fracture may be candidates for vertebroplasty.
我们分析了 VERTOS II 随机试验中保守治疗的骨质疏松性椎体压缩性骨折的自然病程,该试验纳入了 202 例椎体压缩性骨折患者,比较了椎体成形术与保守治疗的效果。我们评估了发生慢性背痛的患者比例及可能的危险因素。
在 VERTOS II 研究中,在定期随访时评估 VAS 评分,直到 1 年随访。我们随访了 95 例接受保守治疗的患者,直到疼痛缓解(VAS 评分≤3)。这些患者在相应的随访间隔被截尾。此外,我们比较了在任何随访间隔 VAS 评分≤3 的患者与在每个随访间隔 VAS 评分>3 的患者的基线临床和影像学数据以及使用的疼痛药物类型,使用逻辑回归分析。
在 1 年的随访期间,95 例患者中有 57 例(60%)疼痛缓解(VAS 评分≤3)。尽管使用了更高类别的止痛药,但在最后一次 12 个月的随访中,仍有 38 例(40%)患者的 VAS 评分≥4,存在疼痛。统计学分析未显示出危险因素。
在 VERTOS II 试验中,大多数接受保守治疗的急性骨质疏松性压缩性骨折患者在最初 3 个月内疼痛缓解明显。然而,1 年后,尽管使用了更高类别的止痛药,仍有相当一部分患者存在致残性疼痛。慢性疼痛的发生没有预测因素。骨折后疼痛持续≥3 个月的患者可能是椎体成形术的候选者。